The World Health Organization (WHO) panel, in its latest statement, has recommended against the use of the remdesivir, an antiviral drug, in hospitalized COVID-19 patients. WHO says there is no evidence that the drug improves mortality.
WHO issued revised guidance on 19th Nov, Thursday in which the WHO’s Guideline Development Group has made a “weak or conditional recommendation against” using remdesivir in hospitalized patients. This recommendation comes after reviewing the clinical data that showed the drug did not increase survival. The group also found the drug had no meaningful effect on whether hospitalized COVID-19 patients would need to be put on ventilators.
However, the group has cautioned that the new recommendation is based on “currently available data,” where the certainty of the evidence is low.
Link to the article: https://www.bmj.com/content/bmj/370/bmj.m3379.full.pdf
Earlier developments:
A trial run by the U.S. National Institutes of Health (NIH) found that remdesivir helped hospitalized COVID-19 patients recover faster compared to placebo.
WHO’s Solidarity trial results last month showed that remdesivir “appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.”
However, in a surprising move, a week after the Solidarity data came out, the FDA approved remdesivir for hospitalized patients, leaving everyone wondering how FDA could approve it even after the publication of negative results of the WHO trial. But FDA in its approval statement cited the NIH- study plus a few other trials that indicated some benefit from remdesivir.
Tags:
The US Food and Drug Administration has granted 'Emergency Use Authorization (EUA)' for Gilead Sciences’ antiviral drug remdesivir to treat COVID-19, the ...
CHICAGO, Ill., USA: The American Dental Association is urging dental professionals across the U.S. to view the Centers for Disease Control and Prevention's ...
Our interest in the significance of T-cell immunity in fighting SARS-CoV-2 infection and in providing resistance to re-infection is only growing more. Now, ...
Mind your mind because a dilapidated one is worse than having none. Dr. Bhavdeep Singh Ahuja emphasizes the importance of mental health in these challenging...
Antibody testing among vaccine beneficiaries has increased manifold recently due to the anxiety over post-vaccination immunity, but are these antibody tests...
The use of saliva has multiple advantages over nasopharyngeal swabs in terms of being non-invasive, its ease of collection without professional help, and ...
MUMBAI, India: Dental colleges in India are currently closed, and dental clinics across the country have been advised to suspend all non-essential ...
Herd immunity is a key concept for epidemic control, which states that only a proportion of a population needs to be immune to an infectious agent for it to...
Dr Ashwini Bhangale (BDS) summarizes the latest updates on the use of masks - from the World Health Organization (WHO), released on 1 Dec 2020 and the ...
The World Health Organization (WHO) has released two new reports that provide the first global recommendations for establishing human genome editing as a ...
Live webinar
Fri. 19 July 2024
5:30 am IST (New Delhi)
Live webinar
Wed. 7 August 2024
3:30 am IST (New Delhi)
Live webinar
Wed. 14 August 2024
4:30 am IST (New Delhi)
Live webinar
Wed. 21 August 2024
6:30 pm IST (New Delhi)
Dr. Jim Lai DMD, MSc(Perio), EdD, FRCD(C)
Live webinar
Thu. 29 August 2024
5:30 am IST (New Delhi)
Live webinar
Mon. 2 September 2024
2:30 pm IST (New Delhi)
Live webinar
Tue. 3 September 2024
8:30 pm IST (New Delhi)
To post a reply please login or register